Skip to main content

Table 4 Variables associated with a teicoplanin initial trough concentration (Cmin) ≥ 20 μg/mL: univariate and multivariate analyses

From: Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Factors No of patients with teicoplanin initial Cmin ≥20 μg/mL (%) Univariate analysis Multivariate analysis
Patients with factor Patients without factor Crude odds ratio (95%CI) P-value Adjusted odds ratio (95%CI) P-value
Enhanced high loading dose regimen 117/149 (78.5%) 150/363 (41.3%) 5.19 (3.33–8.089) < 0.001 7.75 (4.62–12.99) < 0.001
Sex (male) 161/318 (50.6%) 106/194 (54.6%) 0.85 (0.60–1.22) 0.378   
Age (> 65 years) 162/318 (50.9%) 105/194 (54.1%) 0.88 (0.62–1.26) 0.485   
Body mass index< 18.5 59/124 (47.6%) 208/388 (53.6%) 0.79 (0.52–1.18) 0.242   
Body mass index ≥25 47/74 (63.5%) 220/438 (50.2%) 1.73 (1.04–2.87) 0.034 2.33 (1.24–4.38) 0.008
eGFR≥60 mL/min/1.73 m2 164/293 (56.0%) 103/219 (47.0%) 1.43 (1.01–2.04) 0.045 1.15 (0.68–1.95) 0.603
Heart disease 111/208 (53.4%) 156/304 (51.3%) 1.09 (0.76–1.55) 0.648   
Chronic renal failure 47/116 (40.5%) 220/396 (55.6%) 0.55 (0.36–0.83) 0.004 0.62 (0.38–1.03) 0.062
Diabetes mellitus 58/112 (51.8%) 209/400 (52.3%) 0.98 (0.65–1.49) 0.931   
Collagen disease 25/53 (47.2%) 242/459 (52.7%) 0.80 (0.45–1.42) 0.443   
Chronic respiratory disease 14/27 (51.9%) 253/485 (52.2%) 0.99 (0.46–2.15) 0.975   
Inflammatory bowel disease 44/89 (49.4%) 223/423 (52.7%) 0.88 (0.56–1.39) 0.573   
Intensive care unit stay (> 3 days) 34/98 (34.7%) 233/414 (56.3%) 0.41 (0.26–0.65) < 0.001 0.32 (0.19–0.56) < 0.001
Liver cirrhosis/chronic hepatic dysfunction 34/72 (47.2%) 233/440 (53.0%) 0.80 (0.48–1.31) 0.367   
Malignant tumor 99/204 (48.5%) 168/308 (54.5%) 0.79 (0.55–1.12) 0.182   
Total parenteral nutrition 45/102 (44.1%) 222/410 (54.1%) 0.70 (0.43–1.03) 0.070 0.54 (0.32–0.92) 0.022
Serum albumin < 2.5 g/dL (median) 79/217 (36.4%) 188/295 (63.7%) 0.33 (0.23–0.47) < 0.001 0.24 (0.15–0.37) < 0.001
Ventilator use 37/90 (41.1%) 230/422 (54.5%) 0.58 (0.37–0.93) 0.021 1.51 (0.68–3.36) 0.316
Surgery within 28 days 68/158 (43.0%) 199/354 (56.2%) 0.59 (0.40–0.86) 0.006 0.47 (0.30–0.74) 0.001
Transplantation 6/8 (75.0%) 261/504 (51.8%) 2.79 (0.56–13.97) 0.289   
Steroid use 42/85 (49.4%) 225/427 (52.7%) 0.88 (0.55–1.40) 0.580   
Immunosuppressive therapy 18/28 (64.3%) 249/484 (51.4%) 1.70 (0.77–3.76) 0.186   
Anticancer therapy 26/47 (55.3%) 241/465 (51.8%) 1.15 (0.63–2.10) 0.648   
MRSA infections 72/139 (51.8%) 195/373 (52.3%) 0.98 (0.66–1.45) 0.923   
Complicated MRSA infections 54/99 (54.5%) 213/413 (51.6%) 1.13 (0.73–1.75) 0.595   
APACHE II score ≥ 15 54/130 (41.5%) 213/382 (55.8%) 0.56 (0.38–0.84) 0.005 0.78 (0.44–1.35) 0.371
  1. eGFR, estimated glomerular filtration rate, APACHE II Acute physiology and chronic health evaluation II score